E-bike and scooter crashes driving more brain injuries

medicalxpress - The growing use of electric bikes and scooters has caused a surge in brain and spine injuries among urban riders and pedestrians, a new study shows. Led by NYU Langone Health researchers, the study found that these injuries now account for nearly 7% of tr…

AI Summary: A new analysis links the rise of e‑bikes and scooters to a measurable increase in traumatic brain injuries and trauma admissions, accounting for roughly 7% of related cases in the examined data. Researchers urge better helmet uptake, infrastructure changes and policy action to curb preventable head injuries before cities regret their micro‑mobility love affair.

CDC: Proportion of extensively drug-resistant Shigella isolates increasing

medicalxpress - The proportion of extensively drug-resistant (XDR) Shigella isolates in the United States increased from 2011–2015 to 2023, according to research published in the April 9 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality…

AI Summary: Federal health officials report a worrying uptick in extensively drug‑resistant Shigella strains, complicating treatment and raising the risk of harder‑to‑control outbreaks. The data underscore the need for enhanced surveillance, hygiene measures, antibiotic stewardship and rapid public‑health responses as standard antibiotics lose reliability. Try not to spread it—literally.

Three gene therapy pioneers just won the Breakthrough Prize. This is their story

Ryan Cross / endpoints - A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one of the most prominent recognitions yet for the field ...

AI Summary: Three gene‑therapy researchers received the Breakthrough Prize in recognition of foundational work that enabled the first CRISPR-based sickle cell therapy. The award highlights decades of basic and translational research that turned genome editing from lab curiosity into a tangible clinical remedy, with winners sharing a multimillion‑dollar prize and public acclaim.

First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape

oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]

AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.

Growing liver tissue directly in the body could ease donor organ shortage

medicalxpress - In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative capacity to repair or compensate for it. Once this "point of no return" has been reached, the only option is an organ tran…

AI Summary: Scientists report a technique to grow liver tissue directly inside the body as a potential solution to donor organ shortages, demonstrating functional hepatic tissue formation in preclinical or early clinical models. The promising results have been followed by an editorial expression of concern over methodology and data, prompting calls for independent validation before wider clinical use.

FDA updates mifepristone safety study status

Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…

AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.

First-in-human trial primes immune system to accept donor livers

medicalxpress - UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.

AI Summary: A first‑in‑human study reports a novel immune‑priming approach that enabled three liver transplant recipients to stop standard lifelong immunosuppression. The intervention appears to induce tolerance to donor tissue, reducing dependence on anti‑rejection drugs and their toxic side effects, offering a potential shift in transplant management if larger trials confirm these early results.

'I'm not being listened to' - new health plan launched as women say they are still ignored

bbc - New plans to improve healthcare for women and girls have been set out, but will they change anything?

AI Summary: Health officials unveiled a new women's health plan, but many women say the rollout feels performative and that their concerns remain unheard. Patient advocates warn the initiative risks repeating past mistakes unless it embeds lived experience, transparent accountability and genuine co-design—otherwise it's policy theater with a glossy brochure.

Florida surgeon charged with manslaughter after removing wrong organ

Mariah Taylor / beckershospitalreview - Thomas Shaknovsky, MD, a Florida surgeon, was charged April 13 with second-degree manslaughter in connection with the death of a 70-year-old man during surgery. The Alabama man was vacationing in Florida when he experienced severe pain on his left side, T…

AI Summary: A Florida surgeon has been criminally charged with manslaughter after allegedly removing the wrong organ during an operation that resulted in a patient’s death. Prosecutors say the error was catastrophic, triggering an investigation and renewed scrutiny of surgical safety protocols, oversight practices, and how a single clinical mistake escalates into a criminal case.

Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors

Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…

AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.

ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer

oncodaily - Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors. While therapeutic options have expanded …

AI Summary: The European Society for Medical Oncology released updated clinical practice guidelines for metastatic colorectal cancer, redefining diagnostic pathways, systemic therapy sequencing, and follow‑up standards. The guidance incorporates recent targeted and immunotherapy evidence to recommend practical treatment algorithms, prompting oncology centers to update protocols and payers to reassess coverage as clinicians translate recommendations into routine care.

FDA approves Travere's Filspari as first drug for the kidney disease called FSGS

Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...

AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.

CMS showcases first wave of digital health tools as questions about 'last mile' of adoption remain

fiercehealthcare - On Thursday, Trump administration officials unveiled the first wave of health tech tools as part of a push to make medical records more accessible to Medicare patients.

AI Summary: CMS showcased its first wave of vetted digital health tools via a new "app store" designed to streamline interoperability and distribute standardized applications across health systems. The platform aims to make vetted digital tools easily discoverable, but adoption hurdles, governance questions, and real‑world integration challenges mean hospitals may be cautious before swapping PDFs for plug‑and‑play magic.

Mount Sinai, Anthem reach 3-year agreement

Elizabeth Casolo / beckershospitalreview - Anthem Blue Cross Blue Shield in New York and New York City-based Mount Sinai Health System have established a three-year agreement, both organizations confirmed to Becker’s. The agreement includes hospitals, physicians and other providers. Mount Sinai sa…

AI Summary: Mount Sinai and Anthem reached a three‑year contract restoring in‑network coverage after negotiations, ending a period of uncertainty for patients and clinicians. The deal averts immediate network disruption and signals both sides' willingness to settle—proof that combat can end in compromise when hospitals and insurers remember patients actually use the services.

Baylor Scott & White Health Plan to exit Medicaid, individual markets; cut 321 jobs

Jakob Emerson / beckershospitalreview - Baylor Scott & White Health Plan said April 14 it will exit the Texas Medicaid managed care market and discontinue its individual marketplace plans, affecting roughly 225,000 members and eliminating 321 jobs statewide, according to the Dallas Morning News…

AI Summary: Baylor Scott & White announced it will leave Medicaid individual markets, a move that will shed hundreds of jobs and reshape coverage options for affected enrollees. The decision highlights ongoing financial pressures in public‑program participation and raises practical concerns about access continuity for people reliant on those plans.

Norway's 'Oslo patient' reaches HIV remission after rare stem cell transplant donated by brother

medicalxpress - A Norwegian man has been effectively cured of HIV after receiving a stem cell transplant from his brother, doctors announced on Monday.

AI Summary: A remarkable clinical case: a patient in Norway known as the "Oslo patient" has entered sustained HIV remission following a rare stem‑cell transplant from a donor with genetic resistance to the virus. The outcome offers cautious optimism for curative strategies, though experts stress this remains an exceptional, high‑risk intervention rather than a broadly applicable cure.

One lot of Xanax recalled nationwide over quality issue, FDA says

medicalxpress - A widely used anxiety medication is being pulled from shelves due to "failed dissolution specifications," the U.S. Food and Drug Administration (FDA) said.

AI Summary: Regulators have flagged a quality issue and a manufacturer has recalled a specific lot of Xanax nationwide. Pharmacies and patients have been advised to check lot numbers and return affected pills; health officials emphasize the recall is precautionary, urging anyone with concerns to consult their pharmacist or clinician rather than panic-buy substitutes.

Tenet CIO to retire at year end

Emily Olsen / healthcaredive - Paola Arbour will stay at Tenet on a part-time basis to provide transition and support services through early 2028.

AI Summary: Tenet announced its chief information officer will retire at year‑end, kicking off a leadership transition for a pivotal technology role. The departure forces succession planning and raises questions about continuity for key digital initiatives — the sort of timing CIOs love to call “strategic.”